Cite
HARVARD Citation
Tam, C. et al. (2022). Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet oncology. 23 (8), pp. 1031-1043. [Online].